Information Provided By:
Fly News Breaks for April 23, 2018
NBIX
Apr 23, 2018 | 08:19 EDT
Jefferies analyst Biren Amin says Neurocrine Biosciences' NBI-74778, in Phase II development for the orphan disease congenital adrenal hyperplasia, has retained a low profile to date. The analyst estimates a $300M-plus market in the U.S., which he believes "could support robust uptake." Neurocrine gets no credit for the drug, and as such, early signals of efficacy could rally shares $5-$10 with minimal downside risk, Amin tells investors in a research note. He keeps a Buy rating on Neurocrine with a $105 price target.
News For NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.